Several studies suggest that TP53 gene mutations are potential prognostic biomarkers for cancer patients that undergo immunotherapies, such as head and neck squamous cell cancer, lung adenocarcinoma [10, 11]. The gene discussed is TP53; the disease is lung adenocarcinoma.